FDA Grants Priority Review to Adaptimmune's T-Cell Therapy for Advanced Synovial Sarcoma
The biologics license application for afamitresgene autoleucel, an engineered T-cell receptor drug, was assigned a PDUFA date of August 4, 2024.
The biologics license application for afamitresgene autoleucel, an engineered T-cell receptor drug, was assigned a PDUFA date of August 4, 2024.